These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 7704917)

  • 21. Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
    Ahn HW; Shin WG; Park KJ; Suh OK; Choi JH
    Res Commun Mol Pathol Pharmacol; 1999; 105(1-2):105-13. PubMed ID: 10850374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, physico-chemical properties and penetration activity of alkyl-6-(2,5-dioxopyrrolidin-1-yl)-2-(2-oxopyrrolidin-1-yl)hexanoates as potential transdermal penetration enhancers.
    Brychtova K; Jampilek J; Opatrilova R; Raich I; Farsa O; Csollei J
    Bioorg Med Chem; 2010 Jan; 18(1):73-9. PubMed ID: 19954983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation.
    Narishetty ST; Panchagnula R
    Biopharm Drug Dispos; 2004 Jan; 25(1):9-20. PubMed ID: 14716748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zelrix: a novel transdermal formulation of sumatriptan.
    Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
    Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and in vivo evaluation of an indapamide transdermal patch.
    Ren C; Fang L; Ling L; Wang Q; Liu S; Zhao L; He Z
    Int J Pharm; 2009 Mar; 370(1-2):129-35. PubMed ID: 19114099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palatal mucosa as a route for systemic drug delivery: A review.
    Shakya P; Madhav NV; Shakya AK; Singh K
    J Control Release; 2011 Apr; 151(1):2-9. PubMed ID: 21059376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The transdermal drug delivery system and transcutaneous absorption.
    Morimoto Y; Sugibayashi K; Natsume H
    Acta Derm Venereol Suppl (Stockh); 1994; 185():15-7. PubMed ID: 8091920
    [No Abstract]   [Full Text] [Related]  

  • 29. Transdermal delivery systems.
    Merkle HP
    Methods Find Exp Clin Pharmacol; 1989 Mar; 11(3):135-53. PubMed ID: 2657273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal drug delivery: useful paradigms.
    Potts RO; Cleary GW
    J Drug Target; 1995; 3(4):247-51. PubMed ID: 8820998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentials of new nanocarriers for dermal and transdermal drug delivery.
    Neubert RH
    Eur J Pharm Biopharm; 2011 Jan; 77(1):1-2. PubMed ID: 21111043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reverse iontophoretic monitoring in premature neonates: feasibility and potential.
    Sekkat N; Naik A; Kalia YN; Glikfeld P; Guy RH
    J Control Release; 2002 May; 81(1-2):83-9. PubMed ID: 11992681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal drug delivery: a review of pharmaceutics, pharmacokinetics, and pharmacodynamics.
    Moore L; Chien YW
    Crit Rev Ther Drug Carrier Syst; 1988; 4(4):285-349. PubMed ID: 3133121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations.
    Pfister WR; Hsieh DS
    Med Device Technol; 1990; 1(5):48-55. PubMed ID: 10171148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iontophoresis--is there a future for clinical application?
    Theiss U; Kuhn I; Lücker PW
    Methods Find Exp Clin Pharmacol; 1991 Jun; 13(5):353-9. PubMed ID: 1921572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular effects of transdermally delivered bupranolol in rabbits: effect of chemical penetration enhancers.
    Babu RJ; Dhanasekaran M; Vaithiyalingam SR; Singh PN; Pandit JK
    Life Sci; 2008 Jan; 82(5-6):273-8. PubMed ID: 18096189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin.
    Pannier AK; Arora V; Iversen PL; Brand RM
    Int J Pharm; 2004 May; 275(1-2):217-26. PubMed ID: 15081152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcutaneous theophylline collection in preterm infants.
    Murphy MG; Peck CC; Conner DP; Zamani K; Merenstein GB; Rodden D
    Clin Pharmacol Ther; 1990 Apr; 47(4):427-34. PubMed ID: 2328550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermal peptide delivery using colloidal carrier systems.
    Goebel A; Neubert RH
    Skin Pharmacol Physiol; 2008; 21(1):3-9. PubMed ID: 17912018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Proceedings of new drug delivery systems and their applications in the traditional Chinese drugs].
    Zhou SH; Xiao XH; Yuan HL; Zhao YL; Shan LM; Cai GM
    Zhongguo Zhong Yao Za Zhi; 2003 Jul; 28(7):589-92. PubMed ID: 15139097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.